AstraZeneca PLC (NASDAQ:AZN) Shares Sold by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 25.7% in the third quarter, Holdings Channel reports. The firm owned 13,620 shares of the company’s stock after selling 4,707 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in AstraZeneca were worth $1,061,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in AZN. McClarren Financial Advisors Inc. grew its position in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares in the last quarter. GHP Investment Advisors Inc. purchased a new stake in AstraZeneca during the 2nd quarter worth approximately $26,000. Capital Performance Advisors LLP acquired a new stake in shares of AstraZeneca during the third quarter worth approximately $28,000. Ashton Thomas Securities LLC bought a new stake in shares of AstraZeneca in the third quarter worth $45,000. Finally, Hollencrest Capital Management grew its holdings in AstraZeneca by 38.4% during the 3rd quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after acquiring an additional 192 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on AZN shares. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Trading Up 1.4 %

Shares of AstraZeneca stock opened at $67.18 on Wednesday. The business has a fifty day simple moving average of $69.77 and a 200-day simple moving average of $76.57. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The firm has a market cap of $208.30 billion, a price-to-earnings ratio of 32.14, a price-to-earnings-growth ratio of 1.19 and a beta of 0.45. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS. On average, equities analysts forecast that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.